References
- Hasskarl J, Ihorst G, De Pasquale D, etal. Association of multiple myeloma with different neoplasms: systematic analysis in consequtive patients with myeloma. Leuk Lymphoma 2010;51; 247–259.
- Barlogie B, Tricot G, Haessler J, etal. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008;111:94–100.
- Kaldor JM, Day NE, Clarke EA, etal. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7–13.
- Shulman LN. The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am 1993;7:325–335.
- Niparuck P, Kanoksil W, Chuncharunee S, etal. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients. Leuk Lymphoma 2010 Sep 17 [Epub ahead of print].
- Carney DA, Seymour JF. Therapy-related myelodysplasia and fludarabine combination therapy for patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia - do the benefits justify the risk? Leuk Lymphoma 2010;11:1957–1959.
- Carney DA, Westerman DA, Tam CS, etal. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010 Oct 21. [Epub ahead of print].
- Curtis RE, Freedman MD, Ron E, etal. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. BethesdaNational Cancer Institute, NIH2006.
- Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2009;28:830–834.